Imagion Biosystems Ltd. · ASX:IBX
Imagion Biosystems — Investor Presentation (June 2020)
7 slides from Imagion Biosystems's investor presentation, Jun 23, 2020
Slide 1: Investor Webcast: MagSense First-in-Human Study
For personal use only Investor Webcast MagSense First-in-Human Study 10:30am AEST, 23 June 2020 www.imagionbiosystems.com
Slide 2: Study Overview
Study Overview For personal use only Staging of HER2 metastatic breast cancer by the detection of tumor cells in lymph nodes Phase I Study Multi-Site in AUS Timing • Primary endpoint • 3-5 clinical sites in • Enrolment is testing for Australia (VIC and expected to patient safety NSW) commence in Q4
Slide 3: Advantages of an Australian Study
For personal use only Advantages of an Australian Study Favorable regulatory and clinical research Multi-modal study will provide an indication of MagSense targeted environment reduces risk of delays nanoparticles for use with Ability to add MRI with Siemens Healthcare magnetic relaxometry and M
Slide 4: Pathway to Study Initiation
For personal use only Pathway to Study Initiation CRO Appointed Human Research Ethics Committee (HREC) Submission and Approval Completion of Manufacturing of the MagSense™ nanoparticles Clinical sites and Principal Investigators contracted Targeting Subject Enrolment Q4 2020 IMAGIONBIOSYSTEMS.COM
Slide 5: Transformative for Medical Imaging
For personal use only Transformative for Medical Imaging The MagSense™ HER2 Metastatic Breast Cancer Test • Works within current standard cancer diagnosis and staging protocols. • Replaces current non-functional imaging such as MRI or ultrasound used to assess for enlarged lymph nodes but which cann
Slide 6: Q&A
For personal use only Q&A Please raise your hand in Zoom or leave a question in the Q&A section, and the IBX team will respond in turn. IMAGIONBIOSYSTEMS.COM | 6
Slide 7: Contact
For personal use only Contact: www.imagionbiosystems.com info@imagionbio.com ASX: IBX
Imagion Biosystems — Investor Presentation (June 2020) on 6ix